Cargando…
Hyperpolarized (13)C-Pyruvate to Assess Response to Anti-PD1 Immune Checkpoint Inhibition in YUMMER 1.7 Melanoma Xenografts
There is currently no consensus to determine which advanced melanoma patients will benefit from immunotherapy, highlighting the critical need to identify early-response biomarkers to immune checkpoint inhibitors. The aim of this work was to evaluate in vivo metabolic spectroscopy using hyperpolarize...
Autores principales: | Farah, Chantale, Neveu, Marie-Aline, Bouzin, Caroline, Knezevic, Zorica, Gallez, Bernard, Leucci, Eleonora, Baurain, Jean-François, Mignion, Lionel, Jordan, Bénédicte F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917169/ https://www.ncbi.nlm.nih.gov/pubmed/36768822 http://dx.doi.org/10.3390/ijms24032499 |
Ejemplares similares
-
Combined HP (13)C Pyruvate and (13)C-Glucose Fluxomic as a Potential Marker of Response to Targeted Therapies in YUMM1.7 Melanoma Xenografts
por: Farah, Chantale, et al.
Publicado: (2022) -
Metabolic imaging using hyperpolarized (13)C‐pyruvate to assess sensitivity to the B‐Raf inhibitor vemurafenib in melanoma cells and xenografts
por: Acciardo, Stefania, et al.
Publicado: (2019) -
Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas
por: Acciardo, Stefania, et al.
Publicado: (2018) -
Impact of Inhibition of the Mitochondrial Pyruvate Carrier on the Tumor Extracellular pH as Measured by CEST-MRI
por: Buyse, Chloé, et al.
Publicado: (2021) -
Probing Early Tumor Response to Radiation Therapy Using Hyperpolarized [1-(13)C]pyruvate in MDA-MB-231 Xenografts
por: Chen, Albert P., et al.
Publicado: (2013)